1. Introduction {#sec1}
===============

Gastrointestinal cancers (GICs) are one of the most common causes of cancer-related deaths with a high mortality worldwide, which mainly include esophageal, gastric, and colorectal cancers (EC, GC, and CRC). In addition to aging and expansion of world population, cancer-causing behaviors play a key role in the increasing largely global burden of GIC, such as smoking and changes in dietary patterns \[[@B1]\]. There are many therapy strategies applicable to GIC patients, such as surgery, neoadjuvant chemoradiotherapy, and adjuvant chemoradiotherapy \[[@B2]\], and GIC patients at early stage could be curable by receiving suitable treatment with a 90% five-year overall survival, However, five-year overall survivals are still poor for patients with advanced stages \[[@B3], [@B4]\]. Consequently, early diagnosis and selection of high-risk individuals with poor prognosis are important in the recovery of patients. However, effective methods to evaluate prognosis of GIC patients are still lacking nowadays. Currently, mounting reports have reported that noncoding RNA could be used to predict the prognosis of GIC patients, For example, microRNAs are potentially eligible for predicting the survival of GIC patients \[[@B5]\]. Many studies indicated that long noncoding RNAs (lncRNAs) could competitively suppress microRNAs by acting as molecular sponges recently \[[@B6]\]. Besides, aberrant expression of specific lncRNAs as molecular biomarkers was associated closely with prognosis of GIC patients and involved in targeted therapy, which might promote the development of novel prevention strategies and advanced therapies \[[@B7]--[@B12]\].

lncRNA is a long (more than 200 nucleotides) class of noncoding RNA that is often expressed in a disease-, tissue-, or stage-specific manner \[[@B13]\]. According to recent estimate, more than 28000 distinct lncRNAs are encoded by human genome and they regulate gene expression by means of different mechanisms, including chromatin modification, transcription, and posttranscriptional processing, which are becoming attractive therapeutic targets of cancers \[[@B14], [@B15]\]. Such upregulated lncRNA HOXA11-AS expression promotes tumor proliferation and invasion by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1 \[[@B16]\]. lncRNA FEZF1-AS1 recruits and bounds to LSD1 to epigenetically repress downstream gene p21, thereby promoting proliferation \[[@B17]\], and lncRNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability \[[@B18]\]. Furthermore, lncRNA plays crucial roles in the diverse biological processes such as development, differentiation, and carcinogenesis \[[@B19]\]. In addition, lncRNA may induce resistance of an anticancer drug. For example, upregulated lncRNA MALAT1 induces chemoresistance of CRC cells \[[@B20]\].

Recently, mounting evidences have indicated that various lncRNAs can function as oncogenes or tumor suppressor genes and the dysregulation of lncRNA expression as molecular biomarkers presented promising huge prognostic values in GIC patients \[[@B21]--[@B26]\]. However, the ability of evaluating relationship between multiple lncRNA expression and prognosis of GIC patients was limited due to monocentric, small samples and various experimental methods and criteria from different research departments. Therefore, the purpose of the study was to elaborate the relationship between multiple lncRNA expression and prognosis of GIC patients so that further understanding of prognostic values of lncRNAs might promote lncRNA-based target therapeutic development and make a clinical decision that is suitable for the individual quickly.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

To obtain the relevant studies for this meta-analysis, two authors (Weibiao Kang and Qiang Zheng) searched a wide range of database (PubMed, Web of Science, and Embase) independently up to August 27, 2018. Search terms are as follows: "LncRNA", "Long non-coding RNAs", "lncRNAs", "lncRNA", "Long ncRNA", "LincRNAs", "LINC RNA", "Long ncRNAs", "cancer", "tumor", "malignancy", "carcinoma", "neoplasia", "neoplasm", "gastrointestine", "gastroenteric", "colon", "colorectal", "rectum", "intestinal", "gastric", "esophageal", "esophagus", "follow up studies", "prognosis", "prediction", "survival", "hazard ratio", "incidence", and "mortality", which were combined with AND/OR.

2.2. Selection Criteria {#sec2.2}
-----------------------

All eligible studies were assessed and extracted data by the same two investigators independently based on the selection criteria. Inclusion criteria are the following: (1) patients who were diagnosed as having gastrointestinal cancer by pathologists and did not receive any preoperative chemotherapy or radiotherapy before obtaining samples; (2) predicting prognosis of full stage (I--IV) patients on the basis of the expression levels of lncRNAs; (3) the expression levels of lncRNAs were divided into high and low levels; (4) we could obtain overall survival (OS), disease-free survival (DFS), hazard ratio (HR), and 95% confidence interval (95% CI) directly from full text or extract survival data from Kaplan-Meier survival curves. Exclusion criteria are the following: (1) reviews, letters, case reports, statements, and not clinical related studies were excluded; (2) besides non-English and nonhuman studies, articles lack of data were also excluded; (3) studies focused on lncRNA variants or relationship between lncRNA expression and prognosis in different histological types of GIC. We resolved disagreements by discussing with the third investigator (Changjun Yu) and got consensus finally.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

The two authors (Weibiao Kang and Qiang Zheng) extracted data independently and got consensus finally. The characteristics collected of individual articles were as follows: author, year of publication, nation of population enrolled, number of patients, HR and 95% CI (OS/DFS), cut-off value, method, sample type, and follow-up. We assessed the quality of each study by using the guidelines for meta-analysis of observation studies in epidemiology (MOOSE) \[[@B27]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was conducted by Review Manager 5.2 (provided by Cochrane collaboration). *P* \< 0.01 was considered statistically significant. The heterogeneity among studies was calculated by *Q* and *I*^2^ tests. *P* \> 0.10 in combination with *I*^2^ \< 50% indicated low heterogeneity; fixed-effect models should be used. Otherwise, random-effect model would be used finally. For some studies from which we could not extract HR and corresponding 95% CI (OS/DFS) directly, Engauge Digitizer 4.1 software was applied to obtain the necessary points and the relevant data from Kaplan-Meier survival curves, then HR and corresponding 95% CI were calculated by published methods proposed by Tierney et al. \[[@B28]\]. Additionally, forest plots of the pooled HR values and funnel plots used to analyse qualitatively publication bias were presented. Furthermore, we also applied sensitivity analysis for this meta-analysis.

3. Results {#sec3}
==========

3.1. Study Identification and Characteristics {#sec3.1}
---------------------------------------------

According to the selection criteria, a total of 111 articles (21 EC, 47 GC, and 44 CRC; one study involved GC and CRC) involving 13103 patients (3123 with EC, 4972 with GC, and 5008 with CRC) were identified and included in the meta-analysis; specific steps were showed in [Figure 1](#fig1){ref-type="fig"} \[[@B10]--[@B13], [@B15]--[@B26], [@B29]--[@B123]\]. Most of the studies taken into account refer to Asian population, especially china. Cut-off values of high or low lncRNA expression were mostly median or mean. Detection methods of lncRNA expression were mainly RT-PCR (reverse transcription PCR) or ISH (in situ hybridization). Sample types were almost from tissues. As for clinical outcome indicators, 74 studies \[[@B10]--[@B13], [@B16], [@B18]--[@B23], [@B25], [@B26], [@B29], [@B31]--[@B33], [@B36], [@B38], [@B40], [@B41], [@B43]--[@B47], [@B50], [@B51], [@B53]--[@B58], [@B61], [@B63], [@B64], [@B66]--[@B68], [@B71]--[@B74], [@B77], [@B78], [@B83], [@B85], [@B86], [@B88], [@B89], [@B91], [@B92], [@B96]--[@B102], [@B105]--[@B107], [@B109]--[@B112], [@B115]--[@B119], [@B121], [@B122]\] included overall survival (OS), 8 studies \[[@B17], [@B24], [@B30], [@B34], [@B79], [@B95], [@B114], [@B123]\] included disease-free survival (DFS), and another 29 studies \[[@B15], [@B35], [@B37], [@B39], [@B42], [@B48], [@B49], [@B52], [@B59], [@B60], [@B62], [@B65], [@B69], [@B70], [@B75], [@B76], [@B80]--[@B82], [@B84], [@B87], [@B90], [@B93], [@B94], [@B103], [@B104], [@B108], [@B113], [@B120]\] included both OS and DFS. We have identified 74 lncRNAs which were associated closely with poor prognosis of GIC patients, including 58 significantly upregulated lncRNA expression and 16 significantly downregulated lncRNA expression (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). Moreover, 47 of the included studies revealed relative mechanisms, and 12 of them investigated the correlation between lncRNAs and microRNAs ([Table 3](#tab3){ref-type="table"}).

3.2. Meta-Analysis Findings {#sec3.2}
---------------------------

Random-effect and fixed-effect models were applied to evaluate the pooled hazard ratio (HR) and its corresponding 95% confidence interval (CI) of OS or DFS based on the heterogeneity level. The pooled HR value (95% CI) of OS which correlated with the expression of lncRNA-UCA1 \[[@B37], [@B64], [@B66], [@B96], [@B97]\] was 2.42 (1.68--3.49) with low heterogeneity (*P* = 0.99, *I*^2^ = 0%) and statistically significant (*P* \< 0.00001) ([Figure 2](#fig2){ref-type="fig"}). For all included studies, the pooled HR values (95% CI) of OS related to different lncRNA expressions in EC, GC, and CRC patients were 1.92 (1.70--2.16), 1.96 (1.77--2.16), and 2.10 (1.87--2.36), respectively. And the pooled HR value (95% CI) of OS related to different lncRNA expressions was 2.00 (1.87--2.13) in GIC with moderate heterogeneity (*P* = 0.0001, *I*^2^ = 37%) and statistically significant (*P* \< 0.00001) ([Figure 3](#fig3){ref-type="fig"}). Besides, the pooled HR value (95% CI) of DFS related to different lncRNA expressions was 1.92 (1.73--2.14) in GIC patients with moderate heterogeneity (*P* = 0.006, *I*^2^ = 41%) and statistically significant (*P* \< 0.00001) ([Figure 4](#fig4){ref-type="fig"}). Furthermore, funnel plots of included studies related to lncRNA-UCA1, OS, and DFS in GIC patients were presented in Figures [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}, respectively. These figures are approximately symmetrical, and we can think that there is no obvious publication bias.

4. Discussion {#sec4}
=============

GIC is still a huge threat to human health in spite of ongoing emergence of new anticancer drugs because of chemotherapy resistance and metastasis inducing poor prognosis. In the last decade, more and more studies focused on the clinical roles of lncRNAs and many reports indicated that lncRNA can be a molecular biomarker in gastrointestinal cancer patients for predicting prognosis. However, the prognostic value of lncRNAs that need to be clarified, verified, and summarized was limited by various research centers and small samples.

The purpose of this study was to elucidate the relationship between multiple lncRNA expressions and prognosis of GIC patients. Through big data meta-analysis, we provided evidence to illustrate the prognostic value of aberrantly expressed lncRNAs in GIC patients. The results from this meta-analysis showed that the pooled HR values (95% CI) of OS and DFS related to different lncRNA expressions in GIC patients were 2.00 (1.87--2.13) and 1.92 (1.73--2.14), respectively, which implied that aberrantly expressed lncRNAs may serve as cancer biomarkers in GIC patients. By detecting expression levels of specific lncRNAs in tissue or other body fluids, we cannot only make appropriate clinical decisions based on different prognoses but also monitor the therapeutic efficacy of GIC patients receiving different treatments. In addition, lncRNAs may be used to screen patients at high risk at the early stage based on abnormal expression. Moreover, elevated lncRNA-UCA1 expression promoted tumor cell migration, invasion, EMT, proliferation, and chemoresistance and inhibited its apoptosis by different target genes, which was associated with poor prognosis. For example, Jiao et al. \[[@B66]\] reported that lncRNA-UCA1 as a competing endogenous RNA (ceRNA) of Sox4 enhanced tumor cell proliferation by targeting miR-204 and Sox4 and Bian et al. \[[@B96]\] demonstrated that lncRNA-UCA1 promoted tumor cell proliferation and 5-fluorouracil resistance by functioning as a ceRNA of miR-204-5p. The pooled HR value (95% CI) of OS which correlated with the expression of lncRNA-UCA1 was 2.42 (1.68--3.49) with low heterogeneity (*P* = 0.99, *I*^2^ = 0%) and statistically significant (*P* \< 0.00001). Therefore, lncRNA-UCA1 as a molecular biomarker can be applied in predicting the prognosis of GIC patients. Generally, predicting prognosis of patients and exploring mechanisms of lncRNAs play pivotal roles in clinical decision-making and development of novel targeted gene therapies. Therefore, we summarized the researches involved in mechanisms of lncRNAs; we found that 37 lncRNAs had explicit targets and 11 lncRNAs as ceRNAs regulated cancer progression by sponging corresponding microRNAs. These studies demonstrated that the potential relationship between lncRNAs and microRNAs plays a key role in tumor pathogenesis and promoted carcinogenic study and development of gene therapy. Many studies focusing on the same lncRNA revealed different targets, and the underlying correlation between lncRNAs and microRNAs was still unclear. In the future, we should focus on the interrelationship between lncRNA and microRNA or other types of RNA, in achieving targeted treatment by simultaneous intervention of multiple types of RNA.

Several limitations should not be ignored. First, most of included patients were from East Asia, especially China, which makes our conclusions may just be suitable for Chinese patients. Second, the cut-off values and detection methods in evaluating different lncRNA expressions were various in different included studies, which may lead to heterogeneity between studies. Third, language bias was also one of the limitations, because we only enrolled English papers in the meta-analysis. Fourth, the majority of authors were generally more inclined to report positive results so that the pooled effect values calculated might overestimated the predictive significance of lncRNAs in prognosis of GIC patients; the publication bias have reached a consensus. Fifth, we calculated the HR estimates from the Kaplan-Meier survival curves because of some studies from which we could not extract HR and 95% CI directly. Sixth, the confounding factors in some included studies without the adjusted HR values would lead to high heterogeneity.

In summary, this meta-analysis supports the fact that specific lncRNAs are significantly related to the prognosis of GIC patients and may serve as novel markers for predicting the prognosis in GIC patients. In addition, lncRNAs may have a promising contribution to lncRNA-based targeted therapy and clinical decision-making in the future.
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![Forest plot showing the pooled HR and corresponding 95% CI of OS related to the expression level of lncRNA UCA1 in gastrointestinal cancer patients. HR: hazard ratio; CI: confidence interval; OS: overall survival.](DM2018-5340894.002){#fig2}
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![Forest plot showing the pooled HR (95% CI) of DFS related to the expression level of different lncRNAs in GIC patients. HR: hazard ratio; CI: confidence interval; DFS: disease-free survival; GIC: gastrointestinal cancer.](DM2018-5340894.004){#fig4}
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![Funnel plot of included studies: aberrantly expressed lncRNAs related to overall survival in gastrointestinal cancer patients. EC: esophageal cancer; GC: gastric cancer; CRC: colorectal cancer.](DM2018-5340894.006){#fig6}

![Funnel plot of included studies: aberrantly expressed lncRNAs related to disease-free survival in gastrointestinal cancer patients.](DM2018-5340894.007){#fig7}

###### 

Characteristics of studies and lncRNA expression related to OS in GIC patients.

  References                     lncRNAs (*n* = 105)   Year         Nations   Number (*n* = 12178)   OS         Cut-off value   Detection methods               Sample types   Follow-up   
  ------------------------------ --------------------- ------------ --------- ---------------------- ---------- --------------- ------------------------------- -------------- ----------- --------------
  Sun et al. \[[@B13]\]          RNAGAS5^↓^            2014         China     89 GC                  2.43^∗^    1.29--4.59      Median                          RT-PCR         Tissue      \<40
  Li et al. \[[@B29]\]           SNHG20^↑^             2016         China     107 CRC                2.97^∗^    1.51--5.82      YI                              RT-PCR         Tissue      \<40
  Kong et al. \[[@B15]\]^!^      PVT1^↑^               2015         China     80 GC                  2.09^∗^    1.07--4.10      Median                          RT-PCR         Tissue      \<40
  Qi et al. \[[@B31]\]           AGAP2-AS1^↑^          2017         China     50 GC                  2.67^\#^   1.45--4.93      Median                          RT-PCR         Tissue      6--36^\#^
  Chen et al. \[[@B32]\]         XIST^↑^               2016         China     106 GC                 3.11       1.67--3.78      Median                          RT-PCR         Tissue      \<120
  Ye et al. \[[@B33]\]           lnc-GNAT1-1^↓^        2016         China     68 CRC                 2.16^∗^    1.01--4.63      Median                          RT-PCR         Tissue      \<20
  Saito et al. \[[@B21]\]        ATB^↑^                2015         Japan     183 GC                 3.50^∗^    1.73--7.44      Median                          RT-PCR         Tissue      0.192--134.4
  Yuan et al. \[[@B35]\]^!^      PVT1^↑^               2016         China     111 GC                 2.28^∗^    1.05--4.93      Median                          RT-PCR         Tissue      20--48
  Ye et al. \[[@B36]\]           CLMAT3^↑^             2015         China     90 CRC                 2.05^∗^    1.10--3.82      Dichotomize                     RT-PCR         Tissue      \<45
  Zheng et al. \[[@B37]\]^!^     UCA1^↑^               2015         China     112 GC                 2.35^∗^    1.22--4.52      Dichotomize                     RT-PCR         Tissue      \<92
  Chen et al. \[[@B38]\]         NEAT1^↑^              2015         China     96 EC                  1.92^∗^    1.40--6.49      YI                              RT-PCR         Tissue      \<80
  Wang et al. \[[@B39]\]^!^      CCAT2^↑^              2016         China     108 GC                 2.11^∗^    1.44--3.20      Median                          RT-PCR         Tissue      \<70
  Zhao et al. \[[@B22]\]         HOTAIR^↑^             2015         China     168 GC                 1.47^∗^    1.04--2.06      Median                          RT-PCR         Tissue      \<70
  Zhang et al. \[[@B40]\]        Sox2ot^↑^             2016         China     132 GC                 2.05^∗^    1.28--3.30      Median                          RT-PCR         Tissue      \<96
  Chen et al. \[[@B41]\]         HIF1A-AS2^↑^          2015         China     83 GC                  1.72^∗^    1.00--2.96      Median                          RT-PCR         Tissue      \<60
  Li et al. \[[@B10]\]           HOTAIR^↑^             2013         China     100 EC                 1.91       1.06--4.00      125-fold                        RT-PCR         Tissue      \<60
  Yue et al. \[[@B42]\]^!^       FER1L4^↓^             2015         China     70 CC                  3.99^∗^    1.67--9.01      Median                          RT-PCR         Tissue      \<80
  He et al. \[[@B43]\]           CCAT1^↑^              2014         China     48 CC                  2.09^\#^   1.42--3.06      Median                          RT-PCR         Tissue      24--37^\#^
  Yin et al. \[[@B44]\]          MEG3^↓^               2015         China     62 CRC                 0.13^∗^    0.02--0.99      Mean                            RT-PCR         Tissue      \<60
  Nie et al. \[[@B45]\]          MIR31HG^↓^            2016         China     48 CC                  2.35^\#^   1.15--4.79      Median                          RT-PCR         Tissue      3--36^\#^
  Park et al. \[[@B46]\]         BM742401^↓^           2013         Korea     113 GC                 1.03^∗^    0.57--1.88      Median                          RT-PCR         Tissue      \<80
  Liu et al. \[[@B23]\]          CRNDE-h^↑^            2016         China     148 CRC                2.39^∗^    1.30--4.39      Median                          RT-PCR         Serum       1--65
  Li et al. \[[@B47]\]           PANDAR^↑^             2017         China     102 CRC                3.08^∗^    0.84--7.89      Median                          RT-PCR         Tissue      \<60
  Chen et al. \[[@B48]\]^!^      H19^↑^                2016         China     128 GC                 1.96^∗^    0.97--3.97      Median                          RT-PCR         Tissue      20--48
  Zou et al. \[[@B49]\]^!^       Sox2ot^↑^             2016         China     155 GC                 3.24^∗^    1.24--6.43      Median                          RT-PCR         Tissue      \<70
  Jiang et al. \[[@B50]\]        TUG1^↑^               2016         China     218 EC                 1.40^∗^    1.01--1.95      NR                              RT-PCR         Tissue      12--72
  Svoboda et al. \[[@B51]\]      HOTAIR^↑^             2014         Czech     84 CRC                 5.9        1.34--26.1      Median                          RT-PCR         Blood       12--54
  Wang et al. \[[@B52]\]^!^      OTUB1-isoform 2^↑^    2016         China     156 GC                 1.54       1.04--2.27      Median                          RT-PCR         Tissue      \<80
  Guo et al. \[[@B53]\]          FTX^↑^                2015         China     187 CRC                2.37       1.42--2.74      Median                          RT-PCR         Tissue      \<60
  Pan et al. \[[@B54]\]          FOXCUT^↑^             2014         China     82 EC                  2.13^\#^   1.38--3.29      Mean                            RT-PCR         Tissue      1--72
  Zhou et al. \[[@B55]\]         LET^↓^                2014         China     93 GC                  2.28       1.30--5.18      Mean                            RT-PCR         Tissue      \<60
  Hu et al. \[[@B56]\]           linc-UBC1^↑^          2015         China     85 GC                  3.56^\#^   1.71--7.39      Median                          RT-PCR         Tissue      \<100
  Wang et al. \[[@B57]\]         CCAT2^↑^              2015         China     86 GC                  2.41       1.19--5.42      Mean                            RT-PCR         Tissue      \<60
  Ren et al. \[[@B58]\]          HOTTIP^↑^             2015         China     156 CRC                2.15       1.31--3.42      Median                          RT-PCR         Tissue      33--65
  Liu et al. \[[@B59]\]^!^       DANCR^↑^              2015         China     104 CRC                2.13^∗^    1.16--7.06      Median                          RT-PCR         Tissue      \<60
  Wang et al. \[[@B60]\]^!^      ZEB1-AS1^↑^           2015         China     87 EC                  2.37       1.28--6.12      Median                          RT-PCR         Tissue      \<61
  Li et al. \[[@B61]\]           BANCR^↑^              2015         China     184 GC                 1.51^∗^    1.03--2.23      Median                          RT-PCR         Tissue      5--93
  Ma \[[@B62]\]^!^               PANDAR^↑^             2016         China     100 GC                 3.68       1.13--12.06     NR                              RT-PCR         Tissue      2--36
  Huang et al. \[[@B63]\]        MALAT1^↑^             2016         China     132 EC                 6.64       2.95--14.95     NR                              RT-PCR         Tissue      \<60
  Ni et al. \[[@B64]\]           UCA1^↑^               2015         China     54 CRC                 3.11^\#^   0.59--16.39     Median                          RT-PCR         Tissue      9--51^\#^
  Wu et al. \[[@B25]\]           uc002yug.2^↑^         2014         China     684 EC                 2.61       1.50--3.78      NR                              RT-PCR         Tissue      \<140
  Sun et al. \[[@B16]\]          HOXA11-AS^↑^          2016         China     85 GC                  2.85^\#^   1.65--4.91      Median                          ISH            Tissue      9--36
  Peng et al. \[[@B65]\]^!^      NEAT1^↑^              2016         China     56 CRC                 1.70^\#^   1.04--2.80      NR                              RT-PCR         Tissue      \<60
  Jiao et al. \[[@B66]\]         UCA1^↑^               2016         China     66 EC                  2.24^\#^   1.17--4.29      Median                          RT-PCR         Tissue      5--30^\#^
  Liu and Shangguan \[[@B67]\]   CARLo-5^↑^            2017         China     240 GC                 2.41^∗^    1.13--5.94      0.041                           RT-PCR         Tissue      \<60
  Ma et al. \[[@B11]\]           CCAL^↑^               2016         China     252 CRC                2.25^∗^    1.35--3.74      Median                          RT-PCR         Tissue      \<100
  Yang et al. \[[@B18]\]         GHET1^↑^              2014         China     42 GC                  1.90^\#^   0.53--6.85      Median                          RT-PCR         Tissue      7--40^\#^
  Wu et al. \[[@B68]\]           HOTAIR^↑^             2014         China     120 CC                 3.92       1.23--12.50     5-fold                          RT-PCR         Tissue      10--72
  Zhou et al. \[[@B69]\]^!^      ROR^↑^                2016         China     60 CC                  7.22^∗^    2.43--17.43     Median                          RT-PCR         Tissue      \<80
  Yang et al. \[[@B70]\]^!^      Loc554202^↓^          2016         China     178 CRC                2.45       1.34--7.74      Median                          RT-PCR         Tissue      \<70
  Lü et al. \[[@B71]\]           BC032469^↑^           2016         China     58 GC                  2.78^\#^   0.95--8.09      Mean                            RT-PCR         Tissue      \<23
  Su et al. \[[@B72]\]           BLACAT1^↑^            2017         China     48 CRC                 1.50^∗^    1.32--1.70      Mean                            RT-PCR         Tissue      \<60
  Hu et al. \[[@B12]\]           GAPLINC^↑^            2014         China     90 GC                  1.54^∗^    1.22--1.94      Median                          ISH            Tissue      \<80
  Fu et al. \[[@B73]\]           NEAT1^↑^              2016         China     140 GC                 1.61       1.03--2.53      Median                          RT-PCR         Tissue      \<96
  Yao et al. \[[@B26]\]          RP11-766N7.4^↓^       2017         China     50 EC                  2.14^\#^   1.10--4.15      Median                          RT-PCR         Tissue      32--60^\#^
  Xie et al. \[[@B74]\]          SPRY4-IT1^↑^          2014         China     92 EC                  2.05       1.04--4.03      Median                          RT-PCR         Tissue      3--60
  Peng \[[@B75]\]^!^             SPRY4-IT1^↑^          2015         China     175 GC                 0.82^∗^    0.31--1.57      Median                          RT-PCR         Tissue      \<60
  Nie et al. \[[@B76]\]^!^       ZFAS1^↑^              2016         China     54 GC                  2.08^\#^   1.11--3.93      Median                          RT-PCR         Tissue      3--36^\#^
  Ohtsuka et al. \[[@B77]\]      H19^↑^                2016         USA       117 CC                 1.28^∗^    1.08--1.50      0.64                            RT-PCR         Tissue      \<90
  Li et al. \[[@B20]\]           MALAT1^↑^             2017         China     68 CRC                 2.17^\#^   1.32--3.55      Median                          RT-PCR         Tissue      1--51^\#^
  Zhou et al. \[[@B78]\]         AFAP1-AS1^↑^          2016         China     162 EC                 1.89^∗^    1.22--2.92      Median                          RT-PCR         Tissue      6--72
  Sun et al. \[[@B80]\]^!^       RP11-119F7.4^↓^       2015         China     96 GC                  1.20^\#^   0.84--1.71      Median                          RT-PCR         Tissue      \<100
  Zhang et al. \[[@B81]\]^!^     ANRIL^↑^              2014         China     120 GC                 1.74^∗^    1.04--2.93      3-fold                          RT-PCR         Tissue      \<60
  Li et al. \[[@B82]\]^!^        NEAT1^↑^              2015         China     239 CRC                1.70^∗^    1.18--2.45      2-fold                          RT-PCR         Tissue      \<60
  Chen et al. \[[@B83]\]         LINC00152^↑^          2016         China     97 GC                  1.66^∗^    1.01-2.73       Median                          RT-PCR         Tissue      \<60
  Chen et al. \[[@B19]\]         FEZF1-AS1^↑^          2016         China     153 CRC                2.40^∗^    1.07--5.41      NR                              ISH            Tissue      \<100
  Han et al. \[[@B84]\]^!^       H19^↑^                2016         China     83 CRC                 1.43^∗^    1.24--1.79      3-fold                          RT-PCR         Tissue      \<50
  Yang et al. \[[@B85]\]         GAPLINC^↑^            2016         China     180 CRC                2.21^∗^    1.38--3.57      NR                              ISH            Tissue      \<100
  Jin et al. \[[@B86]\]          HULC^↑^               2016         China     54 GC                  1.92^\#^   1.00--3.67      2-fold                          RT-PCR         Serum       11--32^\#^
  Cao et al. \[[@B87]\]^!^       BC200^↑^              2016         China     70 EC                  2.24^∗^    1.12--4.49      Median                          RT-PCR         Tissue      \<50
  Cao et al. \[[@B88]\]          SPRY4-IT1^↑^          2016         China     84 CRC                 3.21^∗^    1.55--6.67      2.87-fold                       RT-PCR         Tissue      3--36
  Gao et al. \[[@B89]\]          linc-UBC1^↑^          2017         China     96 CRC                 2.43^∗^    1.09--5.42      Median                          RT-PCR         Tissue      \<60
  Wang et al. \[[@B90]\]^!^      AFAP1-AS1^↑^          2016         China     52 CRC                 2.36       1.11--5.01      Median                          RT-PCR         Tissue      \<50
  Ge et al. \[[@B91]\]           PCAT-1^↑^             2013         China     108 CRC                3.12       1.36--7.19      NR                              RT-PCR         Tissue      \<100
  Deng et al. \[[@B92]\]         91H^↑^                2014         China     72 CRC                 3.66       1.66--8.10      2.86-fold                       RT-PCR         Tissue      2--36
  Sun et al. \[[@B93]\]^!^       AK098081^↑^           2016         China     84 CRC                 1.90^∗^    1.39--2.58      Mean                            RT-PCR         Tissue      1--118^\#^
  Xu et al. \[[@B94]\]^!^        FENDRR^↓^             2014         China     158 GC                 1.76       1.04--3.12      Median                          RT-PCR         Tissue      20--48
  Bian et al. \[[@B96]\]         UCA1^↑^               2016         China     90 CRC                 2.40^∗^    1.04-5.50       Median                          RT-PCR         Tissue      \<100
  Zuo et al. \[[@B97]\]          UCA1^↑^               2017         China     37 GC                  2.92^∗^    1.07--7.96      Median                          RT-PCR         Tissue      \<40
  Lu et al. \[[@B98]\]           PANDAR^↑^             2017         China     124 CRC                3.53^∗^    1.41--4.45      Median                          RT-PCR         Tissue      \<60
  Lv et al. \[[@B99]\]           MEG3^↓^               2016         China     96 EC                  2.12       1.05--4.27      NR                              RT-PCR         Tissue      \<120
  Xu et al. \[[@B100]\]          TUSC7^↓^              2017         China     63 CRC                 2.92       1.03--8.33      NR                              RT-PCR         Tissue      \<120
  Ma et al. \[[@B101]\]          DUXAP8^↑^             2016         China     72 GC                  2.37^\#^   1.39--4.05      Median                          RT-PCR         Tissue      5--36^\#^
  Fei et al. \[[@B103]\]^!^      LINC00982^↓^          2016         China     106 GC                 2.87^∗^    1.34--6.17      Median                          RT-PCR         Tissue      20--48
  Chen et al. \[[@B104]\]^!^     SNHG15^↑^             2016         China     106 GC                 2.93^∗^    1.30--6.58      Median                          RT-PCR         Tissue      20--48
  Tan et al. \[[@B105]\]         SPRY4-IT1^↑^          2017         China     106 CRC                2.34^∗^    1.14--4.83      Mean                            RT-PCR         Tissue      \<70
  Wang and Xing \[[@B106]\]      ZFAS1^↑^              2016         China     159 CRC                1.88^∗^    1.01--3.53      Median                          RT-PCR         Tissue      \<101
  Yao et al. \[[@B107]\]         MALAT-1^↑^            2016         China     137 EC                 1.27^\#^   0.90--1.80      0.5-fold                        RT-PCR         Tissue      3--36^\#^
  Liu et al. \[[@B108]\]^!^      BANCR^↑^              2016         China     142 EC                 0.95^∗^    0.21--0.95      Median                          RT-PCR         Tissue      1--60^\#^
  Chen et al. \[[@B109]\]        HOTAIR^↑^             2013         China     78 EC                  2.40^∗^    1.35--4.28      Mean                            RT-PCR         Tissue      2--60
  Hu et al. \[[@B102]\]^a^       Linc00152^↑^          2016         China     205 EC                 1.89       1.22--2.58      Upper 95% CI in control group   RT-PCR         Plasma      \<60
  POU3F3^↑^                      1.82                  1.17--2.51                                                                                                                          
  CFLAR^↑^                       1.68                  1.08--2.32                                                                                                                          
  Yu et al. \[[@B110]\]          u50535^↑^             2018         China     98CRC                  4.01^∗^    1.06--15.14     NR                              RT-PCR         Tissue      \<60
  Jiang et al. \[[@B111]\]       CRNDE^↑^              2017         China     251CRC                 1.69^∗^    1.05--2.74      NR                              ISH            Tissue      1--117
  Cui et al. \[[@B112]\]         HEIH^↑^               2018         China     84CRC                  1.46^∗^    1.02--2.08      Median                          RT-PCR         Tissue      \<60
  Wu et al. \[[@B113]\]^!^       GHRLOS^↓^             2017         China     366CRC                 1.96^∗^    1.34--2.86      1/2-fold                        RT-PCR         Tissue      5--85
  Li et al. \[[@B115]\]          ZEB1-AS1^↑^           2017         China     24GC                   2.36^∗^    1.41--3.96      Median                          RT-PCR         Tissue      72
  Huang et al. \[[@B116]\]       LINC00673^↑^          2017         China     73GC                   2.38^∗^    1.12--5.06      2-fold                          RT-PCR         Tissue      \<20
  Li et al. \[[@B117]\]          PVT1^↑^               2017         China     104ESCC                2.75^∗^    1.35--5.59      Median                          RT-PCR         Tissue      \<80
  Shi et al. \[[@B118]\]         ZFAS1^↑^              2017         China     246ESCC                1.59^∗^    1.07--2.36      Median                          RT-PCR         Tissue      114
  Wu et al. \[[@B119]\]          XIST^↑^               2017         China     127ESCC                2.4^∗^     1.44--4.01      Median                          RT-PCR         Tissue      \<80
  Ba et al. \[[@B120]\]          LINC00673^↑^          2017         China     79GC                   2.56^∗^    1.01--4.54      Median                          RT-PCR         Tissue      \<50
  Zhu et al. \[[@B121]\]         SNHG1^↑^              2017         China     108CRC                 3.17^∗^    1.55--6.21      Median                          RT-PCR         Tissue      \<50
  Yang et al. \[[@B122]\]        LINC01133^↓^          2018         China     149ESCC                2.18^∗^    1.23--3.85      Median                          RT-PCR         Tissue      \<60

^a^One study involved lncRNA Linc00152, lncRNA POU3F3, and lncRNA CFLAR. ∗ indicates adjusted HR; \# indicates calculated HR of OS and follow-up time; ! indicates studies included OS and DFS; ↑ or ↓ indicates upregulated or downregulated with poor prognosis. OS: overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; EC: esophageal cancer; GC: gastric cancer; CRC: colorectal cancer; GIC: gastrointestinal cancer; NR: no report; YI: Youden index; RT-PCR: reverse transcription PCR; ISH: in situ hybridization.

###### 

Characteristics of studies and lncRNAs expression related to DFS in GIC patients.

  References                   lncRNAs (*n* = 37)   Year         Nations   Number (*n* = 4360)   DFS        Cut-off value   Detection methods   Sample types   Follow-up   
  ---------------------------- -------------------- ------------ --------- --------------------- ---------- --------------- ------------------- -------------- ----------- ------------
  Kong et al. \[[@B15]\]^!^    PVT1^↑^              2015         China     80GC                  2.22^∗^    1.13--4.44      Median              RT-PCR         Tissue      \<40
  Liu et al. \[[@B17]\]        FEZF1-AS1^↑^         2017         China     82GC                  1.52^\#^   0.88--2.63      2-fold              RT-PCR         Tissue      1--43^\#^
  Fan et al. \[[@B30]\]        LINC00261^↓^         2016         China     138GC                 1.81^∗^    1.06--3.10      Median              RT-PCR         Tissue      20--48
  Xu et al. \[[@B34]\]         PVT1^↑^              2017         China     190GC                 1.75       1.25--2.56      Mean                RT-PCR         Tissue      1--85
  Yuan et al. \[[@B35]\]^!^    PVT1^↑^              2016         China     111GC                 2.21^∗^    1.11--4.40      Median              RT-PCR         Tissue      20--48
  Zheng et al. \[[@B37]\]^!^   UCA1^↑^              2015         China     112GC                 2.55^∗^    1.33--4.97      Dichotomize         RT-PCR         Tissue      \<92
  Wang et al. \[[@B39]\]^!^    CCAT2^↑^             2016         China     108GC                 2.31^∗^    1.55--3.42      Median              RT-PCR         Tissue      \<70
  Yue et al. \[[@B42]\]^!^     FER1L4^↓^            2015         China     70CC                  4.51^∗^    1.99--9.02      Median              RT-PCR         Tissue      \<80
  Chen et al. \[[@B48]\]^!^    H19^↑^               2016         China     128GC                 1.29^∗^    1.00-1.65       Median              RT-PCR         Tissue      20--48
  Zou et al. \[[@B49]\]^!^     Sox2ot^↑^            2016         China     155GC                 3.84^∗^    1.87--7.33      Median              RT-PCR         Tissue      \<70
  Wang et al. \[[@B24]\]       NR_034119^↓^         2016         China     107CRC                1.93^∗^    1.04--3.61      NR                  RT-PCR         Serum       11--74
  Wang et al. \[[@B52]\]^!^    OTUB1-isoform 2^↑^   2016         China     156GC                 1.50^∗^    1.02--2.20      Median              RT-PCR         Tissue      \<80
  Liu et al. \[[@B59]\]^!^     DANCR^↑^             2015         China     104CRC                2.40^∗^    1.39--7.28      Median              RT-PCR         Tissue      \<60
  Wang et al. \[[@B60]\]^!^    ZEB1-AS1^↑^          2015         China     87EC                  2.7        1.38--8.35      Median              RT-PCR         Tissue      \<61
  Ma et al. \[[@B62]\]^!^      PANDAR^↑^            2016         China     100GC                 2.36       1.15--4.83      NR                  RT-PCR         Tissue      2--36
  Peng et al. \[[@B65]\]^!^    NEAT1^↑^             2016         China     56CRC                 2.39^\#^   1.37--4.19      NR                  RT-PCR         Tissue      \<60
  Zhou et al. \[[@B69]\]^!^    ROR^↑^               2016         China     60CC                  5.64^∗^    1.92--16.58     Median              RT-PCR         Tissue      \<80
  Yang et al. \[[@B70]\]^!^    Loc554202^↓^         2016         China     178CRC                2.75       1.55--7.93      Median              RT-PCR         Tissue      \<70
  Peng et al. \[[@B75]\]^!^    SPRY4-IT1^↑^         2015         China     175GC                 1.74^∗^    1.32--2.48      Median              RT-PCR         Tissue      \<60
  Nie et al. \[[@B76]\]^!^     ZFAS1^↑^             2016         China     54GC                  1.83^\#^   1.07--3.15      Median              RT-PCR         Tissue      3--36^\#^
  Xu et al. \[[@B79]\]^a^      LSINCT5^↑^           2014         China     71GC                  1.08^∗^    1.29--3.56      Mean                RT-PCR         Tissue      \<72
  74CRC                        1.30^∗^              1.11--3.84   Mean      RT-PCR                Tissue     \<72                                                           
  Sun et al. \[[@B80]\]^!^     RP11-119F7.4^↓^      2015         China     96GC                  1.16^\#^   0.81--1.65      Median              RT-PCR         Tissue      \<100
  Zhang et al. \[[@B81]\]^!^   ANRIL^↑^             2014         China     120GC                 1.72^∗^    1.04--2.84      3-fold              RT-PCR         Tissue      \<60
  Li et al. \[[@B82]\]^!^      NEAT1^↑^             2015         China     239CRC                1.80^∗^    1.27--2.55      2-fold              RT-PCR         Tissue      \<60
  Han et al. \[[@B84]\]^!^     H19^↑^               2016         China     83CRC                 1.52^∗^    1.30--1.90      3-fold              RT-PCR         Tissue      \<50
  Cao et al. \[[@B87]\]^!^     BC200^↑^             2016         China     70EC                  2.17^∗^    1.12--4.19      Median              RT-PCR         Tissue      \<50
  Wang et al. \[[@B90]\]^!^    AFAP1-AS1^↑^         2016         China     52CRC                 2.12       1.03-4.35       Median              RT-PCR         Tissue      \<50
  Sun et al. \[[@B93]\]^!^     AK098081^↑^          2016         China     84CRC                 1.40^\#^   0.86--2.28      Mean                RT-PCR         Tissue      1--118^\#^
  Xu et al. \[[@B94]\]^!^      FENDRR^↓^            2014         China     158GC                 1.8        1.11--2.91      Median              RT-PCR         Tissue      20--48
  Shang et al. \[[@B95]\]      UCA1^↑^              2016         China     77GC                  2.54       1.09--5.92      NR                  RT-PCR         Tissue      \<60
  Fei et al. \[[@B103]\]^!^    LINC00982^↓^         2016         China     106GC                 2.40^∗^    1.19\--4.81     Median              RT-PCR         Tissue      20--48
  Chen et al. \[[@B104]\]^!^   SNHG15^↑^            2016         China     106GC                 2.40^∗^    1.38--4.18      Median              RT-PCR         Tissue      20--48
  Liu et al. \[[@B108]\]^!^    BANCR^↑^             2016         China     142EC                 3.42^\#^   2.29--5.10      Median              RT-PCR         Tissue      1--60^\#^
  Wu et al. \[[@B113]\]^!^     GHRLOS^↓^            2017         China     366CRC                2.02^∗^    1.42--2.88      1/2-fold            RT-PCR         Tissue      5--85
  Yu et al. \[[@B114]\]        linc00261^↓^         2017         China     80GC                  2.57^∗^    1.39--4.20      NR                  RT-PCR         Tissue      \<30
  Ba et al. \[[@B120]\]        LINC00673^↑^         2017         China     79GC                  2.94^∗^    1.23--4.21      Median              RT-PCR         Tissue      \<50
  Xu et al. \[[@B123]\]        FOXD2-AS1^↑^         2018         China     106GC                 1.75^∗^    1.04--2.97      Median              RT-PCR         Tissue      20--48

^a^One study involved GC and CRC. ∗ indicates adjusted HR; \# indicates calculated HR of DFS and follow-up time; ! indicates studies included OS and DFS; ↑ or ↓ indicates upregulated or downregulated with poor prognosis. OS: overall survival; DFS: disease-free survival; HR: hazard ratio; CI: confidence interval; EC: esophageal cancer; GC: gastric cancer; CRC: colorectal cancer; GIC: gastrointestinal cancer; NR: no report; RT-PCR: reverse transcription PCR.

###### 

lncRNAs and relevant targets in gastrointestinal cancer.

  lncRNAs (*n* = 37)   Poor prognosis   Role         Relevant targets                                              Function                                                         Reference
  -------------------- ---------------- ------------ ------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------
  SNHG20^↑^            Upregulated      Oncogene     Cyclin A1, p21                                                Proliferation/invasion/migration                                 \[[@B29]\]
  PVT1^↑^              Upregulated      Oncogene     EZH2, p15, p16, FOXM1                                         Proliferation/metastasis                                         \[[@B15], [@B34]\]
  FEZF1-AS1^↑^         Upregulated      Oncogene     LSD1, P21, FEZF1                                              Proliferation/invasion/migration                                 \[[@B17], [@B19]\]
  AGAP2-AS1^↑^         Upregulated      Oncogene     LSD1, EZH2, P21, E-cadherin                                   Proliferation/migration/invasion                                 \[[@B31]\]
  XIST^↑^              Upregulated      Oncogene     miR-101, EZH2                                                 Proliferation/migration/invasion/growth/metastasis               \[[@B32]\]
  ATB^↑^               Upregulated      Oncogene     miR-200s, ZEB1, ZEB2                                          Invasion/EMT                                                     \[[@B21]\]
  UCA1^↑^              Upregulated      Oncogene     Ets-2, Sox4, miR-204, miR-204-5p, TGF*β*1                     Migration/invasion/proliferation/apoptosis/chemoresistance/EMT   \[[@B64], [@B66], [@B96], [@B97]\]
  NEAT1^↑^             Upregulated      Oncogene     Akt, vimentin, N-cadherin, Zo-1, E-cadherin                   Proliferation/apoptosis/EMT/migration/invasion                   \[[@B65], [@B73]\]
  CCAT2^↑^             Upregulated      Oncogene     EZH2, E-cadherin, LATS2                                       Progression                                                      \[[@B39]\]
  CCAT1^↑^             Upregulated      Oncogene     c-Myc                                                         Proliferation/migration/invasion                                 \[[@B43]\]
  PANDAR^↑^            Upregulated      Oncogene     N-cadherin, vimentin, *β*-catenin, Snail, Twist, E-cadherin   EMT/growth/migration/invasion/apoptosis                          \[[@B98]\]
  H19^↑^               Upregulated      Oncogene     E-cadherin, Rb-E2F, CDK8, *β*-catenin, eIF4A3                 Migration/invasion/proliferation                                 \[[@B48], [@B77], [@B84]\]
  FOXCUT^↑^            Upregulated      Oncogene     FOXC1 (mRNA)                                                  Proliferation/migration/invasion                                 \[[@B54]\]
  MALAT1^↑^            Upregulated      Oncogene     EZH2, miR-218                                                 Chemoresistance/EMT                                              \[[@B20]\]
  uc002yug.2^↑^        Upregulated      Oncogene     RUNX1                                                         Proliferation/migration/invasion                                 \[[@B25]\]
  HOXA11-AS^↑^         Upregulated      Oncogene     EZH2, LSD1, miR-1297                                          Growth/migration/invasion/apoptosis                              \[[@B16]\]
  CCAL^↑^              Upregulated      Oncogene     AP-2α                                                         Progression/multidrug resistance                                 \[[@B11]\]
  GHET1^↑^             Upregulated      Oncogene     c-Myc (mRNA)                                                  Proliferation                                                    \[[@B18]\]
  ROR^↑^               Upregulated      Oncogene     miR-145                                                       Proliferation/migration/invasion                                 \[[@B69]\]
  BC032469^↑^          Upregulated      Oncogene     miR-1207-5p                                                   Proliferation                                                    \[[@B71]\]
  BLACAT1^↑^           Upregulated      Oncogene     EZH2, p15                                                     Proliferation                                                    \[[@B72]\]
  GAPLINC^↑^           Upregulated      Oncogene     miR211-3p, CD44, PSF, NONO, SNAI2                             Invasion                                                         \[[@B12], [@B85]\]
  SPRY4-IT1^↑^         Upregulated      Oncogene     Cyclin D1, MMP2, MMP9, E-cadherin, vimentin                   Proliferation/migration/invasion/EMT/metastasis                  \[[@B75], [@B88]\]
  ZFAS1^↑^             Upregulated      Oncogene     EZH2, LSD1, CoREST, KLF2, NKD2                                Proliferation                                                    \[[@B76]\]
  ANRIL^↑^             Upregulated      Oncogene     PRC2, miR-99a, miR-449a                                       Proliferation                                                    \[[@B81]\]
  LINC00152^↑^         Upregulated      Oncogene     EZH2, p15, p21                                                Proliferation                                                    \[[@B83]\]
  DUXAP8^↑^            Upregulated      Oncogene     EZH2, SUZ12, PLEKHO1                                          Proliferation/migration                                          \[[@B101]\]
  SNHG15^↑^            Upregulated      Oncogene     MMP2, MMP9                                                    Proliferation/migration/invasion                                 \[[@B104]\]
  GAS5^↓^              Downregulated    Suppressor   E2F1, P21                                                     Proliferation                                                    \[[@B13]\]
  lnc-GNAT1-1^↓^       Downregulated    Suppressor   RKIP-NF-*κ*B-Snail                                            Proliferation/migration/invasion/metastasis                      \[[@B33]\]
  FER1L4^↓^            Downregulated    Suppressor   miR-106a-5p                                                   Proliferation/migration/invasion                                 \[[@B42]\]
  MEG3^↓^              Downregulated    Suppressor   p53                                                           Proliferation/apoptosis                                          \[[@B99]\]
  MIR31HG^↓^           Downregulated    Suppressor   E2F1, P21                                                     Proliferation                                                    \[[@B45]\]
  RP11-766N7.4^↓^      Downregulated    Suppressor   Vimentin, N-cadherin, E-cadherin                              Migration/invasion/EMT                                           \[[@B26]\]
  FENDRR^↓^            Downregulated    Suppressor   FN1, MMP2, MMP9                                               Migration/invasion                                               \[[@B94]\]
  TUSC7^↓^             Downregulated    Suppressor   miR-211-3p                                                    Proliferation                                                    \[[@B100]\]
  LINC00982^↓^         Downregulated    Suppressor   P15, P16                                                      Proliferation                                                    \[[@B103]\]

[^1]: Academic Editor: Giuseppe Biondi-Zoccai
